跳至主要内容
临床试验/ACTRN12623001078640
ACTRN12623001078640招募中Unknown

Pilot study of fibroblast activation factor expression in recurrent/progressive pancreatic cancer and mesothelioma using [68Ga]Ga-FAPI-46 PET imaging.

Sir Charles Gairdner and Osborne Park Health Care Group0 个研究点目标入组 30 人开始时间: 2023年10月10日最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1.Diagnosed with: pancreatic cancer which is locally advanced or recurrent/progressive disease or malignant pleural mesothelioma at initial diagnosis or suspected disease progression.
  • 2.Referred for a clinical [18F]FDG PET/CT scan.
  • 3.Male and females greater than 18 years old.
  • 4.Able to provide informed consent and undergo study procedures

排除标准

  • 1.Currently receiving treatment for pancreatic cancer or mesothelioma (including chemotherapy, radiotherapy or immunotherapy)
  • 2.Pregnant at the time of PET scans
  • 3.Unable to provide informed consent
  • 4.Unable to undergo study procedures
  • 5.Other active neoplastic disease

研究者

发起方
Sir Charles Gairdner and Osborne Park Health Care Group

相似试验